Sugi Predict

Sugi Predict / Targets / GRIA4

GRIA4

Glutamate receptor 4 · P48058 · GRIA4 on Sugi Atlas →

40,959 patent compounds predicted against GRIA4, 22,822 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL338199 SCHEMBL338199 0.67 17/20
SCHEMBL338200 SCHEMBL338200 0.60 17/20
SCHEMBL338391 SCHEMBL338391 0.81 15/20
SCHEMBL338102 SCHEMBL338102 0.55 14/20
SCHEMBL338352 SCHEMBL338352 0.54 13/20
SCHEMBL338482 SCHEMBL338482 0.54 13/20
SCHEMBL147252 SCHEMBL147252 0.43 13/20
SCHEMBL338392 SCHEMBL338392 0.67 11/20
Fanapanel Fanapanel (SCHEMBL353357) 0.51 11/20
SCHEMBL147253 SCHEMBL147253 0.42 10/20
Quisqualate Quisqualate (SCHEMBL136819) 0.45 9/20
Nbqx Nbqx (SCHEMBL120375) 1.00 8/20
SCHEMBL28559 SCHEMBL28559 0.45 6/20
SCHEMBL28560 SCHEMBL28560 0.45 6/20
SCHEMBL166235 SCHEMBL166235 0.51 5/20
Mimosine Mimosine (SCHEMBL41924) 0.42 5/20
L-Mimosine L-Mimosine (SCHEMBL41925) 0.42 5/20
SCHEMBL121942 SCHEMBL121942 0.64 4/20
SCHEMBL195083 SCHEMBL195083 0.61 4/20
(R,S)-Ampa (R,S)-Ampa (SCHEMBL68799) 0.61 4/20

Clinical trials — most relevant to GRIA4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine PHASE4COMPLETED
Effects of the Addition of Metyrapone to Antidepressant Therapy in Depression With Dexamethasone Suppression Test Non-suppression. PHASE4UNKNOWN
Ketamine Treatment Effects on Synaptic Plasticity in Depression PHASE4COMPLETED
TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders PHASE3RECRUITING
Memantine for Refractory OCD Patients PHASE3UNKNOWN
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial PHASE2/PHASE3NOT_YET_RECRUITING
High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia PHASE2UNKNOWN
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia PHASE2COMPLETED
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders PHASE2COMPLETED
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder PHASE2COMPLETED
Brain Imaging, Genetics and Treatment for Major Depression PHASE1WITHDRAWN
PET Imaging of Brain mGluR5 Receptors Using [18F]SP203 PHASE1COMPLETED
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia PHASE1COMPLETED
Antidepressant Effects of NR2B in Major Depression PHASE1COMPLETED
Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers PHASE1COMPLETED
Effect of Gene Variants on Dopamine Receptor Natriuretic Responses PHASE1UNKNOWN
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine EARLY_PHASE1COMPLETED
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease nanCOMPLETED
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy nanUNKNOWN
Acamprosate: Genes Associated With Response nanCOMPLETED
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX nanCOMPLETED
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy) nanUNKNOWN
Genetic Variants Associated With Adolescent Suicide Attempts nanCOMPLETED
Regulation of Arginine-vasopressin (AVP) nanCOMPLETED
CRF vs WCRF or PRF-DRG in CLBP of FJ Origin and RFA Failure of MBDR: Central Sensitization and Aberrant Nerve Sprouting nanUNKNOWN
The Neuroprotective Effect of Dexmedetomidine Preserving Brain Functional Connectivity in Elderly Patients nanCOMPLETED
Mapping Brain Glutamate in Humans: Sex Differences in Cigarette Smokers nanCOMPLETED
Epigenetic and Neurochemical Correlates of Bipolar Disorder nanNOT_YET_RECRUITING
Development of a Novel Glutamate Receptor Ligand for PET Scans in Neuropsychiatric Systemic Lupus Erythematosus nanCOMPLETED
An Assessment of Cognitive Function in Irritable Bowel Syndrome nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a GRIA4 binder may also engage these)

ProteinNameSimilarity
Q9Z2W8 — 1.000 Q9Z2W8 →
Q38PU5 — 1.000 Q38PU5 →
P19493 — 1.000 P19493 →
GRIA2 Glutamate receptor 2 1.000 landscape →
P19492 — 1.000 P19492 →
GRIA3 Glutamate receptor 3 1.000 landscape →
P23819 — 1.000 P23819 →
Q5R4M0 — 1.000 Q5R4M0 →
GRIA1 Glutamate receptor 1 1.000 landscape →
P19491 — 1.000 P19491 →
Q38PU8 — 1.000 Q38PU8 →
P19490 — 1.000 P19490 →
Q9Z2W9 — 1.000 Q9Z2W9 →
Q38PU6 — 1.000 Q38PU6 →
Q38PU7 — 1.000 Q38PU7 →
Q38PU2 — 1.000 Q38PU2 →
B1AS29 — 1.000 B1AS29 →
P42264 — 1.000 P42264 →
P42260 — 1.000 P42260 →
P23818 — 1.000 P23818 →
P39087 — 1.000 P39087 →
Q91755 — 1.000 Q91755 →
GRIK3 Glutamate receptor ionotropic, kainate 3 1.000 landscape →
GRIK2 Glutamate receptor ionotropic, kainate 2 0.999 landscape →
Q38PU3 — 0.998 Q38PU3 →
Q38PU4 — 0.996 Q38PU4 →
A0A2R8QF68 — 0.996 A0A2R8QF68 →
GRIK1 Glutamate receptor ionotropic, kainate 1 0.996 landscape →
P26591 — 0.996 P26591 →
Q60934 — 0.994 Q60934 →